Compare TG Therapeutics Inc (TGTX) vs iShares TIPS Bond ETF (TIP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs iShares TIPS Bond ETF — how do they compare? TG Therapeutics Inc trades at $53.34 (market cap $8.16B), while iShares TIPS Bond ETF trades at $104.65 (market cap $14.17B). The key difference: iShares TIPS Bond ETF is the larger of the two by market cap, and TG Therapeutics Inc is trading nearer its 52-week high, iShares TIPS Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold TG Therapeutics Inc for 15 Days and iShares TIPS Bond ETF for 61 Days on average.
| TGTX | TIP | |
|---|---|---|
Market Cap | $8.16B | $14.17B |
Volume | 1,735,121 | 1,780,688 |
Sector | Health | Fixed Income |
52-Week High | $59.06 | $112.20 |
52-Week Low | $26.94 | $103.98 |
Typical Hold Time | 15 Days | 61 Days |
Enterprise Value | $8.37B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $52.95, up 1.46% today, but faces bearish technical signals with recent earnings misses. The company shows strong profitability with 55.22% net margin and 100.28% ROE, while revenue growth continues with BRIUMVI capturing market share. Recent news includes shareholder litigation investigation and buyout speculation.
Despite earnings volatility, TGTX maintains strong fundamentals with analyst consensus at Buy (84.62%) and $80.50 price target. Key risks include ongoing legal scrutiny and execution on BRIUMVI growth, while institutional accumulation signals confidence in long-term prospects.
TIP trades at $104.24, showing minimal daily movement with a 0.06% gain. Technical indicators signal a bearish trend, while oscillators remain neutral. The ETF's financial ratios are not available in the provided data, limiting fundamental assessment. A dividend of $0.78 is scheduled for August 2026, indicating income potential amid current market volatility driven by rising bond yields and geopolitical tensions.
Outlook is cautious due to bearish technicals and macroeconomic pressures from high Treasury yields. The dividend offers a yield cushion, but investors face risks from bond market instability and inflationary concerns. Monitoring Federal Reserve policy and inflation data is critical for near-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About iShares TIPS Bond ETF
TIP is the flagship ETF for U.S. Treasury Inflation-Protected Securities (TIPS). It tracks an index of government bonds whose principal value adjusts based on the Consumer Price Index (CPI), providing a direct hedge against rising inflation.
Read more on TIP →
